Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy

Overview
This study evaluates 89Zr-Df-IAB22M2C PET imaging to track CD8+ T cells in a colorectal cancer model treated with a GUCY2C-CD3 bispecific antibody. G-Rex® devices were used to expand human T cells prior to adoptive transfer. The tracer effectively monitored dose-dependent T cell infiltration.
What this paper found
A CD8-specific minibody PET tracer, 89Zr-Df-IAB22M2C, tracked dose- and time-dependent recruitment of human CD8+ T cells into colorectal tumors in mice treated with the GUCY2C-CD3 bispecific antibody PF-07062119. NSG mice bearing LS1034 colorectal xenografts received 2 × 10^6 activated, expanded human T cells, then PF-07062119 at 0.03 to 1 mg/kg or a non-targeted CD3 control at 1 mg/kg. Tumor uptake did not differ between doses on day 4 but rose with dose by day 9. At the highest dose, ex vivo gamma counting gave 13.0 %ID/g versus 8.0 %ID/g for the control (p = 0.026), with tumor-to-blood and tumor-to-muscle ratios of 8.6 and 27.8. Tracer uptake correlated moderately with CD8+ cell density by immunohistochemistry (R² = 0.46 and 0.45).
Note: Preclinical study in tumor-bearing mice; the authors note that the CD8 PET imaging technique will need further optimization and validation.
The PET tracer, if clinically validated, could provide a biomarker of CD8+ T cell infiltration, well in advance of morphologic changes. — Kevin P. Maresca, Jianqing Chen, Divya Mathur, Anand Giddabasappa, Adam Root, Jatin Narula, Lindsay King, David Schaer, Jonathan Golas, Keith Kobylarz, Edward Rosfjord, Edmund Keliher, Laigao Chen, Sripad Ram, Eve H. Pickering, James S. Hardwick, Paul A. Rejto, Amira Hussein, Ohad Ilovich, Kevin Staton, Ian Wilson, Timothy J. McCarthy, Molecular Imaging and Biology
Study details
- Authors
- Kevin P. Maresca, Jianqing Chen, Divya Mathur, Anand Giddabasappa, Adam Root, Jatin Narula, Lindsay King, David Schaer, Jonathan Golas, Keith Kobylarz, Edward Rosfjord, Edmund Keliher, Laigao Chen, Sripad Ram, Eve H. Pickering, James S. Hardwick, Paul A. Rejto, Amira Hussein, Ohad Ilovich, Kevin Staton, Ian Wilson, Timothy J. McCarthy
- Institution
- Worldwide Research, Development & Medicine, Pfizer Inc, New York, USA · Regneron Pharmaceuticals, Tarrytown, NY, USA · Generate Biomedicines, Inc, Cambridge, MA, USA · Black Diamond Therapeutics, New York, NY, USA · Invicro, A Konica Minolta Company, New Haven, USA · Evergreen Theragnostics, Jersey City, NJ, USA · Memorial Sloan Kettering Cancer Center, New York, NY, USA · ImaginAb Inc., Inglewood, CA, USA
- Journal
- Molecular Imaging and Biology
- Year
- 2021
- Cell type(s)
- T-Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
Human T cells enriched from healthy-donor blood were activated for 48 h and then transferred to a G-Rex® cell culture device (Wilson Wolf Manufacturing Corporation) for expansion, with human IL-2 added to the medium at 5 ng/ml and replenished after 2 days. The T cells were harvested after 5 days of expansion, the activation beads were removed with a magnet, and the cells were resuspended at 1 × 10^7 cells/ml. Each tumor-bearing mouse then received 2 × 10^6 of these activated, expanded T cells intravenously.
Full citation
Maresca KP, Chen J, Mathur D, et al. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy. Mol Imaging Biol. 2021;23(6):941-951.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.